Drug Profile
ISIS 9125
Alternative Names: IP 9125Latest Information Update: 08 Jun 2001
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Anti-inflammatories; Oligonucleotides
- Mechanism of Action Intercellular adhesion molecule 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Transplant rejection
Most Recent Events
- 08 Jun 2001 No-Development-Reported for Inflammatory bowel disease in USA (Unknown route)
- 08 Jun 2001 No-Development-Reported for Transplant rejection in USA (Unknown route)
- 30 Dec 1998 Preclinical development for Transplant rejection in USA (Unknown route)